PRIA Logo™
S5237119th CongressWALLET

Stop Superbugs Act

Sponsored By: Senator Hassan, Margaret Wood [D-NH]

Introduced

Summary

Funded clinical research network to fight antibiotic resistance. This bill would require the Director of the National Institute of Allergy and Infectious Diseases to award a competitive grant to the Antibiotic Resistance Leadership Group (ARLG) to build a network focused on rapid and community-based trial recruitment, pairing diagnostics with therapies, and collecting patient-reported outcomes.

Show full summary
  • Families and patients: Trials would aim for faster enrollment and routine collection of patient-reported outcomes, so study results reflect real patient experiences.
  • Researchers and drug developers: The ARLG grant would create a structured, competitive pathway to run trials that pair new diagnostics with treatments and speed participant recruitment.
  • Communities: The network must conduct recruitment outreach in community settings, which could broaden trial access beyond major medical centers.
  • Federal funding: The bill authorizes appropriations "as may be necessary" to support the ARLG grant, without a fixed dollar cap.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

New clinical research network for superbugs

This bill would direct the Director of the National Institute of Allergy and Infectious Diseases to award a competitive grant to the Antibiotic Resistance Leadership Group. The grant would create a clinical research network on antibiotic resistance. The network would focus on rapid trial participant recruitment and outreach in community settings. It would also pair new diagnostics with drug trials and develop patient-reported outcome measures. The bill would authorize appropriations of "such sums as may be necessary" to carry out the grant program.

Sponsors & CoSponsors

Sponsor

Hassan, Margaret Wood [D-NH]

NH • D

Cosponsors

  • Sen. Marshall, Roger [R-KS]

    KS • R

    Sponsored 8/4/2026

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation